

RAUCON *BD Executive News*

Vol. 16 # 13 | 9 July 2020

Hot Company News

* Acquisition: **Alexion Pharmaceuticals, Inc** completed the previously announced acquisition of **Portola Pharmaceuticals, Inc.** The acquisition adds Factor Xa inhibitor reversal agent **Andexxa**® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as **Ondexxa**® in Europe, to Alexion's commercial portfolio. 2 Jul 2020 (www.alexion.com)

* Distribution: **Alnylam Pharmaceuticals, Inc.** and **Taiba Middle East**, a leading rare disease company based in the United Arab Emirates, have formed a Distribution Agreement for both **ONPATTRO**® and **GIVLAARI**®, the first-ever commercialised RNAi therapeutics, as well as another late-stage therapy in development for Primary Hyperoxaluria Type 1. 8 Jul 2020 (www.alnylam.com)

* Co-marketing: **CIPLA EQ** and **Boehringer Ingelheim India Pvt.** Ltd. agreed to co-market three new oral anti-diabetics drugs **Oboravo**® (Empagliflozin), **Oboravo Met**® (Empagliflozin+Metformin) and **Tiptengio**® (Empagliflozin + Linagliptin) in India. 29 Jun 2020 (www.cipla.com)

* Co-promotion: **G1 Therapeutics, Inc.** (Nasdaq: GTHX) and **Boehringer Ingelheim** have entered into a co-promotion agreement for **trilaciclib** in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and **Boehringer Ingelheim** will collaborate on the commercialisation of **trilaciclib** for its first potential indication in small cell lung cancer. 30 Jun 2020 (www.g1therapeutics.com)

* Acquisition: **Gilead Sciences, Inc.** will acquire a 49.9 percent equity interest for \$275 million in **Pionyr Immunotherapeutics Inc.**, a privately held company developing first-in-class cancer immunotherapies, and an exclusive option to purchase the remainder of **Pionyr**.

24 Jun 2020 (www.gilead.com)

* Investment: The investment firm **KKR (Kohlberg Kravis Roberts & Co.)** has entered into a definitive agreement to purchase a controlling stake in **J.B. Chemicals & Pharmaceuticals Ltd.**, one of the leading Indian pharmaceutical companies specialising in branded formulations.

As part of the agreement, **KKR** will acquire its stake from the founding **Mody** family at a purchase price of INR 745 per share and make an open offer for an additional 26% of the Company. The **J.B. Chemicals** portfolio includes branded formulations across cardiac, gastrointestinal and anti-infective therapeutic areas. The company's leading brands in India are **Cilacar**, **Metrogyl**, **Nicardia** and **Rantac**. The company currently exports its branded formulations to more than 40 countries. 2 Jul 2020 (www.kkr.com)

* Acquisition: In order to enhance its advanced bioprocess portfolio, **Merck KGaA** acquired **Resolution Spectra Systems**, a Meylan, France-based leader in bioprocess analytical monitoring. The company offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. 1 Jul 2020 (www.merck.de)

* Investment: **Piramal Enterprises Limited** and **The Carlyle Group** announced that **CA Clover Intermediate II Investments** has agreed to invest fresh equity capital for a 20% stake in **Piramal Pharma Limited**, a wholly owned subsidiary of **Piramal Enterprises Limited** that will contain its pharmaceutical businesses. 27 Jun 2020 (www.piramal.com)

* Co-Promotion: **UCB** and **Ferring Pharmaceuticals Inc.** have entered into a co-promotion agreement to commercialise the prefilled syringe formulation of **CIMZIA**® (certolizumab pegol) in the United States, specifically for the treat-

ment of Crohn's disease. 7 Jul 2020 (www.ucb.com)

* Licensing: **uniQure** and **CSL Behring** have entered into a licensing agreement providing **CSL Behring** with exclusive global rights to **etranacogene dezaparvovec**, **uniQure's** investigational gene therapy for patients with hemophilia B. **Etranacogene dezaparvovec** consists of an **AAV5** viral vector carrying a gene cassette with the patent-protected **Padua** variant of **Factor IX (FIX-Padua)**. Under the terms of the agreement, **uniQure** will receive a \$450 million upfront cash payment and be eligible to receive up to \$1.6 billion in payments based on regulatory and commercial milestones. 24 Jun 2020 (uniquore.com/)

* Acquisition: **Unum Therapeutics Inc.**, a biopharmaceutical company focused on developing therapies for solid tumours, today announced it has completed the acquisition of **Kiq LLC**, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. 6 Jul 2020 (unumrx.com)

BD People on the Move

* AM-Pharma: **Laetitia Szaller**, who served as Associate General Counsel, Business Development and M&A, Antitrust at **UCB**, has been hired as General Counsel & Vice President, Business Development. (Press Release 29 Jun 2020)

* BeiGene, Ltd: **Angus Grant**, Ph.D., most recently CEO of the **Dementia Discovery Fund** has been appointed as Chief Business Executive with responsibility for business development and alliance management. (Press Release 1 Jul 2020)